Spots Global Cancer Trial Database for leukemia, acute lymphoblastic
Every month we try and update this database with for leukemia, acute lymphoblastic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | NCT05440409 | Leukemia, Acute... Lymphoblastic L... | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | ||
| Impact of the Use of Zinc in the Prevention of Oral Mucositis in Pediatric Patients With Lymphoblastic Acute Leukemia. | NCT04321850 | Oral Mucositis | Zinc Sulfate 50... Placebo oral ta... | 3 Years - 18 Years | National Institute of Pediatrics, Mexico | |
| Erwinase Master Treatment Protocol | NCT00590915 | Leukemia, Acute... Acute Lymphoid ... | Erwinia L-aspar... | - | Phoenix Children's Hospital | |
| Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | NCT02349178 | Leukemia, Acute... Acute Myeloid L... | Clofarabine Cyclophosphamid... Etoposide | - 39 Years | Medical College of Wisconsin | |
| Impact of the Use of Zinc in the Prevention of Oral Mucositis in Pediatric Patients With Lymphoblastic Acute Leukemia. | NCT04321850 | Oral Mucositis | Zinc Sulfate 50... Placebo oral ta... | 3 Years - 18 Years | National Institute of Pediatrics, Mexico | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | NCT03911128 | Leukemia, Acute... | Observational | 0 Years - 45 Years | Karolinska University Hospital | |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | NCT02799147 | Leukemia, Acute... Acute Myeloid L... Mixed-Lineage A... | Allogeneic stem... Fludarabine mon... Busulfan Bendamustine | 18 Years - 60 Years | St. Petersburg State Pavlov Medical University | |
| Vincristine PK and PD in the AYA Population Compared to Younger Children | NCT02360930 | Leukemia, Acute... Leukemia | 1 Year - 24 Years | Children's Hospital Los Angeles | ||
| CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | NCT02935543 | Leukemia, Acute... | CART 19 | 18 Years - | University of Pennsylvania | |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) | NCT04942730 | Leukemia, Acute... Myeloid Leukemi... Biphenotypic Ac... Lymphoblastic L... Myelodysplastic... Myeloproliferat... | Fludarabine Bendamustine Hy... Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus 5Mg ... | 18 Years - 75 Years | St. Petersburg State Pavlov Medical University | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| Acute Lymphoblastic Leukemia Registry at Asan Medical Center | NCT01761682 | Leukemia, Acute... Precursor B-Cel... Leukemia, Biphe... Leukemia, Lymph... Lymphoblastic L... | Diagnosed as AL... | 15 Years - | Asan Medical Center | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | NCT02935543 | Leukemia, Acute... | CART 19 | 18 Years - | University of Pennsylvania | |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | NCT03911128 | Leukemia, Acute... | Observational | 0 Years - 45 Years | Karolinska University Hospital | |
| Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia | NCT04209244 | Leukemia, Acute... | Eskimo-3 Pure F... Rapeseed Oil | 1 Year - 45 Years | Rigshospitalet, Denmark | |
| Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT02393859 | Leukemia, Acute... | Blinatumomab Dexamethasone Vincrisitne Daunorubicin Methotrexate Ifosfamide PEG-asparaginas... Erwinia-asparag... | 0 Years - 17 Years | Amgen | |
| Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia | NCT04209244 | Leukemia, Acute... | Eskimo-3 Pure F... Rapeseed Oil | 1 Year - 45 Years | Rigshospitalet, Denmark | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
